Literature DB >> 24252695

Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City.

Kara A Livingston1, Jennifer B Rosen2, Jane R Zucker3, Christopher M Zimmerman2.   

Abstract

BACKGROUND AND OBJECTIVES: Mumps outbreaks have been reported among vaccinated populations, and declining mumps vaccine effectiveness (VE) has been suggested as one possible cause. During a large mumps outbreak in New York City, we assessed: (1) VE of measles-mumps-rubella vaccine (MMR) against mumps and (2) risk factors for acquiring mumps in households.
METHODS: Cases of mumps were investigated using standard methods. Additional information on disease and vaccination status of household contacts was collected. Case households completed follow-up phone interviews 78-198 days after initial investigation to ascertain additional cases. Mumps cases meeting the study case definition were included in the analysis. Risk factors for mumps were assessed, and VE was calculated using secondary household attack rates.
RESULTS: Three hundred and eleven households with 2176 residents were included in the analysis. The median age of residents was 13 years (range <1-85), and 462 (21.2%) residents met the study mumps case definition. Among 7-17 year olds, 89.7% received one or more doses of MMR vaccine, with 76.7% receiving two doses. Young adults aged 10-14 years (OR=2.4, CI=1.3-4.7) and 15-19 years (OR=2.5, CI=1.3-5.0) were at highest risk of mumps. The overall 2-dose VE for secondary contacts aged five and older was 86.3% (CI 63.3-94.9).
CONCLUSIONS: The two-dose effectiveness of MMR vaccine against mumps was 86.3%, consistent with other published mumps VE estimates. Many factors likely contributed to this outbreak. Suboptimal MMR coverage in the affected population combined with VE may not have conferred adequate immunity to prevent transmission and may have contributed to this outbreak. Achieving high MMR coverage remains the best available strategy for prevention of mumps outbreaks.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Households; Mumps; Outbreaks; Risk factors; Vaccine effectiveness

Mesh:

Substances:

Year:  2013        PMID: 24252695     DOI: 10.1016/j.vaccine.2013.11.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Mumps: an Update on Outbreaks, Vaccine Efficacy, and Genomic Diversity.

Authors:  Eugene Lam; Jennifer B Rosen; Jane R Zucker
Journal:  Clin Microbiol Rev       Date:  2020-02-26       Impact factor: 26.132

2.  Pre-vaccination IgG screening for mumps is the most cost-effectiveness immunization strategy among Health Care Workers.

Authors:  Luca Coppeta; Ottavia Balbi; Savino Baldi; Antonio Pietroiusti; Andrea Magrini
Journal:  Hum Vaccin Immunother       Date:  2019-03-27       Impact factor: 3.452

3.  Facial extention of ear pathology: infected cholesteatoma causing a parotid abscess.

Authors:  Chrysostomos Tornari; Surojit Pal; Ravi Kumar Lingam; Ali Kalan
Journal:  BMJ Case Rep       Date:  2015-03-20

4.  Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII.

Authors:  Barbara J Kuter; Gary S Marshall; Jaime Fergie; Elvira Schmidt; Manjiri Pawaskar
Journal:  Hum Vaccin Immunother       Date:  2022-02-07       Impact factor: 3.452

Review 5.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2021-11-22

6.  Vaccines for measles, mumps, rubella, and varicella in children.

Authors:  Carlo Di Pietrantonj; Alessandro Rivetti; Pasquale Marchione; Maria Grazia Debalini; Vittorio Demicheli
Journal:  Cochrane Database Syst Rev       Date:  2020-04-20

Review 7.  Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella Control Programs.

Authors:  Peter A C Maple
Journal:  Vaccines (Basel)       Date:  2015-12-09

8.  Recommendation of the Advisory Committee on Immunization Practices for Use of a Third Dose of Mumps Virus-Containing Vaccine in Persons at Increased Risk for Mumps During an Outbreak.

Authors:  Mona Marin; Mariel Marlow; Kelly L Moore; Manisha Patel
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2018-01-12       Impact factor: 17.586

9.  Dynamic transmission model of routine mumps vaccination in Japan.

Authors:  Taito Kitano
Journal:  Epidemiol Infect       Date:  2018-12-03       Impact factor: 2.451

10.  HIV transmission among men who have sex with men due to condom failure.

Authors:  Robert S Remis; Michel Alary; Juan Liu; Rupert Kaul; Robert W H Palmer
Journal:  PLoS One       Date:  2014-09-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.